Revision 1



For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W	Reactivity: H M R Mk	Sensitivity: Endogenous	MW (kDa): 97	Source/Isotype: Rabbit	UniProt ID: #Q13200	Entrez-Gene Id: 5708
Product Usage Information		Application Western Blotting			Dilution 1:1000	
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA and 50% glycerol. Store at – 20°C. Do not aliquot the antibody.				
Specificity/Sensitivity		PSMD2 Antibody recognizes endogenous levels of total PSMD2 protein.				
Species predicted to react based on 100% sequence homology		Hamster, Xenopus, Zebrafish, Bovine				
Source / Purification		Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Lys350 of human PSMD2 protein. Antibodies are purified by protein A and peptide affinity chromatography.				
Background	BackgroundThe 26S proteasome is a highly abundant proteolytic complex involved in the degradation of ubiquitinated substrate proteins. It consists largely of two sub-complexes, the 20S catalytic core particle (CP) and the 19S/PA700 regulatory particle (RP) that can cap either end of the CP. The CP consists of two stacked heteroheptameric β-rings (β ₁₋₇) that contain three catalytic β-subunits and flanked on either side by two heteroheptameric α-rings (α ₁₋₇). The RP includes a base and a lid, ead having multiple subunits. The base, in part, is composed of a heterohexameric ring of ATPase sub belonging to the AAA (ATPases Associated with diverse cellular Activities) family. The ATPase sub unfolded substrate to the catalytic β-subunits. The lid consists of ubiquitin receptors and DUBs that function in recruitment of ubiquitinated substrates and modification of ubiquitin chain topology (' Other modulators of proteasome activity, such as PA28/11S REG, can also bind to the end of the 20 and activate it (1,2). Regulatory particle non-ATPase 1 (RPN1, PSMD2) is a subunit of the 19S/PA700 regulatory particle subcomplex. The PSMD2 protein acts as part of the scaffold for assembly of the 19S/PA700 RP bas subcomplex (3). Research studies demonstrate that PSMD2 binds the intracellular domain of type receptor, indicating that the 26S proteasome may play a role in the TNF signaling pathway (4,5). PS expression correlates with poor prognosis in lung cancer patients, and induced inhibition of PSMD results in decreased proteasome activity and increased apoptosis in lung cancer cells (6).				atalytic core e CP. The CP -subunits and are a and a lid, each of ATPase subunits ATPase subunits xposing the and DUBs that in topology (1,2). e end of the 20S CP atory particle base PA700 RP base omain of type I TNF thway (4,5). PSMD2 pition of PSMD2	
Background References		 Finley, D. (2009) Annu Rev Biochem 78, 477-513. Lee, M.J. et al. (2011) Mol Cell Proteomics 10, R110.003871. Rosenzweig, R. et al. (2008) Nat Struct Mol Biol 15, 573-80. Tsurumi, C. et al. (1996) Eur J Biochem 239, 912-21. Dunbar, J.D. et al. (1997) J Immunol 158, 4252-9. Matsuyama, Y. et al. (2011) Mol Carcinog 50, 301-9. 				
	A				d angligation (a.g.	
Species Reactivi	ty	Species reactivity is de	termined by testing	g in at least one approve	d application (e.g.,	western blot).
Western Blot Buffer		IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.				
Applications Key		W: Western Blotting				
Cross-Reactivity Key		H: Human M: Mouse R: Rat Mk: Monkey				
Trademarks and Patents		Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.				

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.